摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-氨基庚酸甲酯 | 17994-94-4

中文名称
7-氨基庚酸甲酯
中文别名
7-氨基庚酸甲酯盐酸盐
英文名称
methyl 7-aminoheptanoate hydrochloride
英文别名
7-amino-heptanoic acid methyl ester hydrochloride;7-methoxy-7-oxoheptan-1-aminium chloride;methyl 7-aminoheptanoate hydrochloride salt;(7-Methoxy-7-oxoheptyl)azanium;chloride
7-氨基庚酸甲酯化学式
CAS
17994-94-4
化学式
C8H17NO2*ClH
mdl
——
分子量
195.689
InChiKey
CHMAEAFFKRYPQT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    119-121℃

计算性质

  • 辛醇/水分配系数(LogP):
    1.49
  • 重原子数:
    12
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    52.3
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2922499990
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温且干燥

SDS

SDS:31ba81f37d622b4e81dbd0b09c4930c8
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 7-Amino-heptanoic acid methyl ester, HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 7-Amino-heptanoic acid methyl ester, HCl
CAS number: 17994-94-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H17NO2.ClH
Molecular weight: 195.7

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    7-氨基庚酸甲酯 在 palladium on activated charcoal lithium hydroxide 、 TEA 、 氢气双(2-氧代-3-恶唑烷基)次磷酰氯 作用下, 以 四氢呋喃甲醇二氯甲烷 为溶剂, 20.0 ℃ 、101.33 kPa 条件下, 反应 10.0h, 生成 4-(二甲氨基)-N-[7-(羟基氨基)-7-氧庚]苯甲酰胺
    参考文献:
    名称:
    Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation
    摘要:
    Inhibitors of histone deacetylase (HD) bear great potential as new drugs due to their ability to modulate transcription and to induce apoptosis or differentiation in cancer cells. We have described previously analogues of the complex natural HD inhibitors trapoxin B and trichostatin A with activities in the submicromolar range. Here we report structure-activity relationship analyses of further analogues of trichostatin A with respect to in vitro inhibition of maize HD-2 and their ability to induce terminal cell differentiation in Friend leukemic cells. This is the first report that shows the correlation between HD inhibitory activity and action on cancer cells on a larger series of similar compounds. Only the compounds that inhibit HD induce differentiation and/or exert antiproliferative activities in cell culture. Our studies support the use of in vitro systems as screening tools and provide structure-activity relationships that merit further investigation of this interesting target.
    DOI:
    10.1021/jm991091h
  • 作为产物:
    描述:
    7-氨基庚酸盐酸 作用下, 以 甲醇 为溶剂, 生成 7-氨基庚酸甲酯
    参考文献:
    名称:
    Prostaglandin agonists and their use to treat bone disorders
    摘要:
    本发明涉及前列腺素受体激动剂、使用此类前列腺素受体激动剂的方法、含有此类前列腺素受体激动剂的药物组合物以及含有此类前列腺素受体激动剂的试剂盒。这些前列腺素受体激动剂可用于治疗包括骨质疏松症在内的骨骼疾病。
    公开号:
    US06498172B1
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LA DÉGRADATION CIBLÉE DE PROTÉINES DE KINASE 1 ASSOCIÉS AU RÉCEPTEUR DE L'INTERLEUKINE 1
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2021018118A1
    公开(公告)日:2021-02-04
    The present invention relates to compounds comprising an interleukin-1 receptor-associated kinase 1 (IRAK1) protein binding moiety and a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety, and associated methods of use. The compounds are useful as modulators of targeted ubiquitination, especially with respect to IRAK1, which is degraded by the compounds according to the invention.
    本发明涉及包含白细胞介素-1受体相关激酶1(IRAK1)蛋白结合基团和Von Hippel-Lindau(VHL)E3泛素连接酶结合基团的化合物,以及相关的使用方法。这些化合物可用作靶向泛素化的调节剂,特别是在与根据本发明降解的IRAK1相关的情况下。
  • 三环类化合物及其用途
    申请人:上海辉启生物医药科技有限公司
    公开号:CN113121527A
    公开(公告)日:2021-07-16
    本发明公开了一种三环类化合物及其用途。本发明具体公开了一种如式I所示化合物或其药学上可接受的盐。本发明的三环类化合物对HDAC尤其是HDAC6具有很好的抑制作用,并具有较好的选择性,还能够抑制多种肿瘤细胞的增殖;
  • [EN] SELECTIVE HDAC INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE HDAC
    申请人:UNIV COLUMBIA
    公开号:WO2011146855A1
    公开(公告)日:2011-11-24
    This disclosure is related to compounds having the structure (I) wherein Ar1, Ar2, R1 - R6, Z, m, n, o, and p are defined herein. This disclosure also relates to pharmaceutical compositions comprising the above compounds and methods for their use.
    这项披露涉及具有结构(I)的化合物,其中Ar1、Ar2、R1 - R6、Z、m、n、o和p在此处被定义。这项披露还涉及包括上述化合物的药物组合物以及它们的使用方法。
  • Arylsulfonamide derivative and pharmaceutical compositions and use
    申请人:NKK Corporation
    公开号:US05650428A1
    公开(公告)日:1997-07-22
    An arylsulfonamide derivative of the formula (I): ##STR1## wherein R.sup.1 is unsubstituted phenyl or naphthyl, or phenyl substituted by 1 to 3 same or different substituents selected from the group consisting of halogen, alkyl, nitro and alkoxy, R.sup.2 is straight, branched, or branched cyclic alkyl with 1 to 15 carbon atoms, phenyl, phenyloxyl, phenyloxy substituted by one or more halogen atoms, cycloalkyl with 5 to 7 carbon atoms, indolyl, alkylthiol with 1 to 4 carbon atoms, hydroxyl, protected hydroxyl, imidazolyl, pyridyloxyl, or --OSO.sub.2 R.sup.4, R.sup.4 is straight or branched alkyl with 1 to 15 carbon atoms, or unsubstituted phenyl or thienyl, or phenyl or thienyl substituted by 1 to 3 same or different substituents of halogen, alkyl, nitro and alkoxy, R.sup.3 is hydrogen or straight or branched alkyl with 1 to 20 carbon atoms, n is an integer of 0 to 10, p is an integer of 0 to 10, X is a group of the formula --(CH.sub.2)m-A-(CH.sub.2)q-, m and q are independently an integer of 0 to 8, and A is a direct bond or phenylene, or a salt thereof; a process for manufacture thereof and a pharmaceutical composition containing same. The above compound exhibits thromboxane A.sub.2 antagonism.
    根据您的要求,以下是公式(I)的中文翻译: 一种芳基磺酰胺衍生物,其化学公式为(I):##STR1##,其中R.sup.1为未取代的苯基或萘基,或者苯基被1到3个相同的或不同的取代基所取代,这些取代基选自卤素、烷基、硝基和烷氧基;R.sup.2为直链、支链或支链环烷基,含有1到15个碳原子,苯基,苯氧基,苯氧基被一个或多个卤素原子所取代,含有5到7个碳原子的环烷基,吲哚基,含有1到4个碳原子的烷基亚硫酰基,羟基,保护的羟基,咪唑基,吡啶氧基或--OSO.sub.2 R.sup.4;R.sup.4为直链或支链烷基,含有1到15个碳原子,或者未取代的苯基或噻吩基,或者苯基或噻吩基被1到3个相同的或不同的取代基所取代,这些取代基选自卤素、烷基、硝基和烷氧基;R.sup.3为氢或直链或支链烷基,含有1到20个碳原子;n为0到10的整数;p为0到10的整数;X为化学公式--(CH.sub.2)m-A-(CH.sub.2)q-的基团,其中m和q各自独立为0到8的整数,A为直接键或亚苯基;以及其盐;一种制造该化合物的方法以及含有该化合物的药物组合物。上述化合物展现出血栓素A.sub.2拮抗性。
  • Chiral Mercaptoacetamides Display Enantioselective Inhibition of Histone Deacetylase 6 and Exhibit Neuroprotection in Cortical Neuron Models of Oxidative Stress
    作者:Jay H. Kalin、Hankun Zhang、Sophie Gaudrel-Grosay、Giulio Vistoli、Alan P. Kozikowski
    DOI:10.1002/cmdc.201100522
    日期:2012.3.5
    Mercaptoacetamide‐based ligands have been designed as a new class of histone deacetylase (HDAC) inhibitors for possible use in the treatment of neurodegenerative diseases. The thiol group of these compounds provides a key binding element for interaction with the catalytic zinc ion, and thus differs from the more typically employed hydroxamic acid based zinc binding groups. Herein we disclose the chemistry
    基于巯基乙酰胺的配体已被设计为新型的组蛋白脱乙酰基酶(HDAC)抑制剂,可用于治疗神经退行性疾病。这些化合物的硫醇基团提供了与催化锌离子相互作用的关键结合元素,因此不同于更常用的基于异羟肟酸的锌结合基团。本文中,我们公开了一些取代的巯基乙酰胺的化学和生物学性质,目的是提高HDAC6同工型的选择性,同时保持类似于其异羟肟酸类似物的效价。发现向硫醇基团引入立体中心α对HDAC抑制剂效能具有相当大的影响。
查看更多